You need to be logged in to view this video

Connecting Biotechnology and Cannabinoids to Treat Incurable Diseases

Released on Thursday, March 18, 2021BIOTECH
Many experts say we're in the golden age of biotechnology, with this sector presenting tremendous opportunities for investors. While Pre-IPO opportunities are traditionally reserved for institutional funds, now you can get in on the ground-floor of this biotech company working to halt and perhaps even reverse disease progression in people living with debilitating diseases with no cures, such as multiple sclerosis and Parkinson's disease, and rare diseases including systemic sclerosis and Huntington's disease—for which it has Orphan Designation—through the convergence of biology, science, and cannabinoids. Join Dr. Jim DeMesa as he provides further insight into this unique investment opportunity.

Jim DeMesa
Emerald Health Pharmaceuticals, President and CEO

Trending Now

Filter By Category
Filter By Keywords
Live Now

Money, Metals, & Mining Virtual Expo

April 20 - 22, 2021